Research Roundup

OFFICIAL PUBLICATION OF

by its subsidiary APPco

Debbie Rigby 08/08/2017

Debbie Rigby rounds up the latest in research news Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease Analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial provides more evidence of the renoprotective effects of SGLT2 inhibitor empagliflozin in patients with type 2 diabetes and cardiovascular disease.

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

‘Category killer’ CWH has scope for growth

Easier said than done. I agree with you, but you know how hard it is too.

D vL

‘Category killer’ CWH has scope for growth

You're under no obligation to provide advice on that product. In fact, you probably shouldn't because you have not screened…

Bart Pharm

Did wave of protest fail to break?

Are they? STILL SOLICITING BRIBES!

D vL

Did wave of protest fail to break?

Coles and Woolies have been good for competition? Have you not followed the Senate inquiry into the supermarkets and how…

Bart Pharm

Research Roundup

Previous CWH: location rules "indefensible, nonsensical"

Next Weekly Dose: Methylprednisolone

Clinical tips: Timing!

Clinical tips: Movement disorders

Clinical tips: Worms, Worms, Worms

Intranasal Midazolam for at home use

MENU

Previous CWH: location rules "indefensible, nonsensical"

Next Weekly Dose: Methylprednisolone

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.